Chronoscale Holdings Corp quarterly report, Q1 FY2014

Business context and reporting period

The supplied filing is PN Med Group Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2013, not a filing bearing the requested name Chronoscale Holdings Corp. PN Med describes itself as a development-stage company planning to distribute medical supplies and equipment in Chile; it had not commenced revenue-generating operations. Its fiscal year ends March 31.

Financial results and liquidity

  • Revenue: $0 for the quarter and since inception through June 30, 2013.
  • Profit and expenses: Net loss was $23,194, versus $4,895 in the comparable 2012 quarter. Operating expenses were $23,194, including $23,126 in professional fees. No income tax provision was recorded.
  • Cash flow: Operating cash use was $27,244. No financing cash was raised during the quarter; cash fell by $27,244 to $1,931 from $29,175.
  • Balance sheet: Total assets were $1,931, all cash. Current liabilities totaled $10,074, including $9,324 owed to a shareholder and $750 in accrued expenses. The shareholder loan is unsecured, non-interest-bearing, and due on demand. Stockholders’ equity was a deficit of $8,143, compared with positive equity of $15,051 at March 31, 2013.
  • Other measures: Basic and diluted loss per share was reported as $(0.00); weighted average shares were 6,350,000. No investing cash flows or interest or income taxes paid were reported.

Changes versus the prior comparable period

Quarterly net loss increased by $18,299 from $4,895 in 2012, primarily alongside professional fees rising to $23,126 from $4,846. Cash and total assets declined from $29,175 at March 31, 2013 to $1,931 at June 30, 2013. The filing reports no revenue in either comparable quarter.

Outlook, risks, and notable disclosures

  • Management said existing working capital, further advances, and anticipated cash flow were expected to fund operations for the next three months, but also stated the company would need to raise funds within 12 months and had no specific funding plan or financing arrangements in place.
  • The company expects to seek equity or debt financing. Financing may be unavailable or on unacceptable terms; equity or convertible debt issuance could dilute shareholders or carry senior rights. Management anticipates expenses for inventory, startup development, and marketing.
  • The filing identifies substantial doubt about the company’s ability to continue as a going concern, citing no revenue, limited working capital, and no stabilized source of revenue sufficient to cover costs. Management said future operations depend on additional capital, with no assurance of success.
  • Management concluded disclosure controls and procedures were not effective as of June 30, 2013. No material change in internal control over financial reporting was reported for the quarter.
  • No material subsequent events or pending or threatened legal proceedings were disclosed. The company reported no material off-balance-sheet arrangements.

Important facts to verify

  1. Confirm issuer identity: the supplied filing names PN Med Group Inc., not Chronoscale Holdings Corp.
  2. Check the statements’ comparative-period labeling: the cash-flow statement heading appears to label both quarterly columns “Three Months Ended June 30, 2012,” although the figures and related discussion present 2013 and 2012 comparisons.
  3. Verify the company’s funding capacity and terms for any planned financing, given cash of $1,931, liabilities exceeding assets, and the going-concern uncertainty.
  4. Assess the implications of ineffective disclosure controls and the company’s continued lack of revenue-generating operations.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.